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Abstract: Efalizumab is a monoclonal a humanized recombinant IgG1 monoclonal antibody 
which targets the CD11a, the alpha-subunit of LFA-1 (lymphocyte function-associated 
antigen-1). It acts by blocking the T-lymphocyte pathogenetic mechanisms of psoriasis. Throm-
bocytopenia is an adverse event that occurs during therapy. Thrombocytopenia can be mild and 
can occur quite early during treatment, together with leukocytosis. Both adverse events tend to 
normalize with ongoing therapy, or, in cases worsening, with therapy suspension. There have 
been multiple reports of thrombocytopenia associated with efalizumab therapy for the treat-
ment of psoriasis. The general recommendation is to check platelet counts monthly for the ﬁ  rst 
3 months of efalizumab therapy, then every 3 months for the duration of therapy. According 
to our experience on a wide range of patients, it is useful to check platelets every month for 
the ﬁ  rst 6 months of therapy. We report a case of efalizumab-associated thrombocytopenia 
that occurred after 16 weeks of therapy together with clinical worsening of skin lesions. The 
peculiarity of our case is the absence of signs and symptoms linked to thrombocytopenia and 
the quick return to normal platelet count without corticosteroid therapy.
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Introduction
Psoriasis vulgaris, the most common form of psoriasis, is a widespread dermatological 
disease, affecting 2% of the world population (Christophers 2001). The most typical 
psoriatic lesions are erythemato-squamous plaques and the general symptoms are 
itching and burning, which are mainly related to the appearance and extent of the 
lesions. As the clinical appearance of the lesions is strictly linked to epidermal 
changes, it was believed for a long time that psoriasis was a skin pathology linked 
to keratinocytes hyperproliferation and to their abnormal differentiation (Krueger 
et al 1984). It is now known that it is an organ-speciﬁ  c autoimmune disease triggered 
by numerous cell types, among which are T-cells (Krueger et al 1984, 2005). The 
crucial role of T-lymphocytes in the pathogenesis of the disease has been further 
emphasized through the successful results obtained with T cell-targeted agents: the 
biologicals.
Efalizumab is a humanized monoclonal IgG1 antibody directed against CD11a, 
the alpha subunit of leukocyte function-associated antigen 1 on T cells. Leukocyte 
function-associated antigen 1 and intercellular adhesion molecule 1 are co-stimulatory 
molecules expressed on T cells and antigen-presenting cells, respectively, which 
facilitate multiple T-cell-mediated events. Efalizumab inhibits T-cell activation, 
cutaneous trafﬁ  cking, and adhesion to keratinocytes through the blockade of LFA-1/
ICAM-1 binding, steps in the immunologic cascade that lead to the formation of the 
psoriatic plaques (Menter et al 2005).
Many placebo-controlled trials have assessed the safety of efalizumab in patients 
affected by chronic psoriasis (Menter et al 2005). Many studies have assessed the safety Biologics: Targets & Therapy 2008:2(4) 924
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and efﬁ  cacy of efalizumab in long-term trials (Gottlieb et al 
2004; Leonardi et al 2005). Moreover, efalizumab has proved 
to be devoid of serious adverse events, which are common in 
clinical practice (Pearce et al 2006). The most serious adverse 
events in the course of efalizumab therapy (apart from aseptic 
meningitis, which is very rare) are leukocytosis and throm-
bocytopenia, which tend to normalize with ongoing therapy, 
or, in cases worsening, with therapy suspension.
We report the clinical course of a patient with psoriasis, in 
comorbidity (diabetes mellitus), who was successfully treated 
with efalizumab for 4 months. After severe thrombocytopenia 
the patient had to stop the treatment and completely recovered 
after treatment suspension.
Case report
The patient was a 61-year-old Caucasian man with a history 
of psoriasis of almost 2 years. He had used many topicals 
(steroids, vitamin-D3 derivates, hydratation products) and 
systemic therapies (cyclosporine-A and methotrexate) for 
psoriasis.
The patient was treated with cyclosporine-A ﬁ  rst, with 
a temporary improvement in his clinical conditions. After 
3 months, cyclosporine-A gave no further improvement 
of skin lesions and blood pressure was too high. He 
underwent weekly treatment with methotrexate and folic 
acid (from the day after methotrexate injection). He had to 
discontinue this therapy, too, because of a sudden increase 
in transaminases.
The patient started efalizumab treatment in March 2008 at 
the ﬁ  rst dose injection of  0.7 mg/kg and thereafter of 1 mg/kg 
once weekly by subcutaneous injection for 17 weeks. The 
baseline Psoriasis Area and Severity Index (PASI) score 
was 10; visual analog sale (VAS) 70; Patient evaluation of 
Psoriasis severity 40; Medical evaluation of Psoriasis severity 
30. At the ﬁ  rst follow up in April 2008 the patient showed a 
PASI score 2; VAS 0; Patient evaluation of Psoriasis severity 
0; Medical evaluation of Psoriasis severity 0. In June 2008 he 
had a PASI score 3; VAS 0; Patient evaluation of Psoriasis 
severity 10; Medical evaluation of Psoriasis severity 10; with 
clinical worsening of his skin manifestations.
After 1 week of this follow up the patient presented 
erythematous papules and plaques on the trunk, particularly 
on the anterior part of the chest. He referred to the forma-
tion of a 10 cm circular red spot on the right leg after the 
17th efalizumab injection. The previous day, before the 17th 
efalizumab injection, the patient began treatment with an 
analog of insulin (glargine 10 IU). We prescribed an urgent 
hematological examination, with the following results: 
white blood cells 14,100/mm3, platelets 48,000/mm3, ESR 
(erythrosedimentation rate) 48 k/μL. Meanwhile he developed 
a suberythrodermic manifestation (Figure 1) with diffuse 
articular pains, fever, and edema of the hands (Figure 2), 
feet, and pretibial regions. Efalizumab treatment was stopped 
and he was admitted to the Dermatological Clinic. We 
checked hemoculture (in order to exclude septicemia from 
any erytrodermic skin infection), double blood microscopic 
observations, protidogram, Weber test, hydroelectrolitic 
balance, glycemia (4 per day to monitor his diabetes), Addis 
count and daily hematological routine. The initial therapy 
was teicoplanin 200 mg/day iv, paracetamol 500 mg to 
demand, atorvastatin 20 mg po at 21 hours, metformin 
Figure 1 A suberythrodermic status involving large parts of the body. A large, red, 
circular edematous spot can be seen on the anterior pretibial right region.Biologics: Targets & Therapy 2008:2(4) 925
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1 po after dinner, and ½ po 20 minutes before breakfast 
and lunch and 1 po 20 minutes before dinner. We also 
administered a hydrocortisone cream twice per day on 
the lesional skin. One week later, laboratory tests showed 
a reduced thrombocytopenia (platelets 126,000/mm3, 
with microscopic aggregates), moderate leukocytosis 
(12,100/mm3), neutrophilia (83.6 %), anemia (hemoglobin 
HGB 11.2 g/dL), ESR 90 k/μL. On the tenth day after his 
hospitalization there was a further improvement in hema-
tological status: platelets (with microscopic aggregates) 
131,000/mm3, with leukocytosis 14,430/mm3, neutrophilia 
(82%), anemia (hemoglobin 11.85 g/dL), ESR 95 k/ μL. On 
his last day of hospitalization platelets (with microscopic 
aggregates) were 271,000/mm3, white blood cells 9040/mm3, 
neutrophils (58%), hemoglobin HGB 13.2 g/dL.
The hemocultures were negative for any microorganisms, 
as were the feces for occult blood; there were no traces of 
blood in the urine.
The patient returned home with a medical prescription 
for hydrating cream twice daily and narrow band-UVB 3 
times weekly.
After 3 weeks white blood cells were 6890/mm3, platelets 
290,000/ mm3, and all the other blood ﬁ  gurate elements were 
within the normal range. His clinical conditions were notably 
improved (Figures 3 and 4).
Discussion
We have reported a case of efalizumab-associated 
thrombocytopenia in a psoriatic patient with diabetes as 
comorbidity. Efalizumab, in this patient, was chosen for 
Figure 3 Clinical conditions of the patient after efalizumab suspension and platelet 
increase.
Figure 2 The lesions involved also the palmar aspect of both hands with edema and pain.Biologics: Targets & Therapy 2008:2(4) 926
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psoriasis treatment because it has proven effective and safe 
in the treatment of chronic plaque-type psoriasis (Gottlieb 
et al 2004; Pearce et al 2006). Moreover, efalizumab has 
proven particularly useful when psoriasis is associated with 
most comorbidities such as hypertension, diabetes, and 
dyslipidemia; many reports have demonstrated that this 
biologic can improve skin conditions without worsening 
comorbidities (Prignano et al 2008). It is also the only 
biologic for which there is long-term study control, which 
provides further proof of its safety in clinical practice 
(Leonardi et al 2008).
In some patients, mostly after many months of efalizumab 
therapy, papular psoriasis, which has been called “efalizumab 
associated popular psoriasis”, can appear. Clinically it 
is an aggravation of the disease and can be treated with 
an immunosuppressive drug such as cyclosporin-A or 
methotrexate in association with efalizumab for a short 
period according to the patient’s general condition and the 
experience of the dermatologist. Often, during efalizumab 
treatment we observed changes in some hematological 
parameters – moderate leukocytosis (10,000–15,000 white 
blood cell count per mm3), granulocytes/lymphocytes 
ratio, and thrombocytopenia. These adverse events usually 
resolved during treatment without the need to stop therapy. 
Dermatologists who are familiar with biologicals understand 
that leukocytosis and thrombocytopenia are almost always 
detectable during early phases of efalizumab treatment. 
Therefore, these adverse events are not a reason to stop 
treatment but to follow up patients to observe the stabilization 
and thereafter normalization of leukocytes and platelets. 
Most cases of efalizumab-associated thrombocytopenia have 
been documented as causing purpura, petechiae, and muco-
sal membrane bleeding (Scheinfeld 2006). The most likely 
mechanism able to induce thrombocytopenia is probably 
autoantibodies against a component of the platelet membrane, 
although the presence of such antibodies has never been 
detected in the documented cases of efalizumab-induced 
thrombocytopenia (van den Bemt et al 2004).
Because US clinical trials have reported some cases of 
efalizumab-associated thrombocytopenia between 10 and 
16 weeks, US authors recommend monthly platelet counts 
during the ﬁ  rst 4 months of therapy. If the total platelet count 
drops 50,000/mm3 or more between any two consecutive 
counts they suggest frequent control until the count stabilizes. 
We do suggest checking platelets count every month during 
the ﬁ  rst 6 months of therapy. If they drop by 5000/mm3 in 
this time-course platelets should be counted every 10 days in 
order to decide whether to continue or stop therapy.
The interest in our case is linked to the fact that even 
when thrombocytopenia was severe (48,000/mm3), our 
patient presented a worsening of his psoriasis but without 
purpura or signs of bleeding symptoms, as reported in the 
literature for most patients (Scheinfeld 2006). Moreover, 
we did not administer any steroids to our patient because he 
suffered from diabetes and also because, being hospitalized, 
we could monitor continuously his platelets. Considering that 
the median time to normalize platelet number is 9 weeks for 
patients without corticosteroid intake (Grim Hostetler et al 
2007), our patient improved very quickly because there 
was a moderate increase in his platelets after 1 week and a 
Figure 4 The palmar region of both hands was clear.Biologics: Targets & Therapy 2008:2(4) 927
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good shift towards normality after 3 weeks of efalizumab 
suspension therapy (290,000/mm3).
We have considerable experience in the treatment of 
moderate to severe plaque type psoriasis, as in our Italian 
National Protocol “PsoCare” we have enrolled more than 
220 patients receiving efalizumab for psoriasis. Leukocytosis 
and thrombocytopenia are quite common in these patients 
during the ﬁ  rst 16 weeks of therapy, but this was the most 
severe case of thrombocytopenia.
We inform the patients before starting efalizumab treat-
ment of the risks of thrombocytopenia and other adverse 
events.
According to our and other published data (Grim 
Hostetler et al 2007; Leonardi et al 2008) efalizumab can be 
safe and effective for treating psoriasis with proper follow-up 
controls. Moreover these follow-up controls are very cheap 
as they comprise only blood monitoring.
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